中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.019 seconds)

    SINGLE-CHAIN TNF LIGAND FAMILY MOLECULES AND FUSION PROTEINS AND DERIVATIVES THEREOF
    1.
    发明申请
    SINGLE-CHAIN TNF LIGAND FAMILY MOLECULES AND FUSION PROTEINS AND DERIVATIVES THEREOF 审中-公开

    公开(公告)号：US20180094059A1

    公开(公告)日：2018-04-05

    申请号：US15558372

    申请日：2016-03-18

    Applicant: UNIVERSITÄT STUTTGART ,  BIONTECH AG

    Inventor： Ugur SAHIN ,  Roland KONTERMANN ,  Klaus PFIZENMAIER ,  Martin SIEGEMUND ,  Meike HUTT ,  Oliver SEIFERT

    IPC: C07K16/28 ,  C07K16/32 ,  C07K14/705

    CPC classification number: C07K16/2863 ,  C07K14/70575 ,  C07K16/32 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/91

    Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector. Further, the present invention relates to said polypeptides, said nucleic acid or said vector for the use as a medicament or for the use in the diagnosis, prophylaxis or treatment of hyperproliferative disorders and inflammatory disorders.

    Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
    5.
    发明申请
    Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy 有权
    鉴定表面相关抗原的肿瘤诊断和治疗

    公开(公告)号：US20140120085A1

    公开(公告)日：2014-05-01

    申请号：US14036969

    申请日：2013-09-25

    Applicant: BioNTech AG

    Inventor： Özlem TÜRECI ,  Ugur SAHIN ,  Sandra SCHNEIDER ,  Gerd HELFTENBEIN ,  Volker SCHLÜTER ,  Dirk USENER ,  Philippe THIEL ,  Michael KOSLOWSKI

    IPC: C07K14/47

    CPC classification number: A61K39/39558 ,  A61K39/395 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/53

    Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.

    Abstract translation: 本发明的分离的截短的脱骨髓蛋白4（DSG4）多肽剪接变体的特征在于缺乏在具有SEQ ID NO：75的多核苷酸序列的DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。还公开了 是在患者中诊断癌症或监测其过程的方法。 该方法包括在患者的组织样品中检测包含由具有SEQ ID NO：75的多核苷酸序列的DSG4基因或截短的DSG4多肽剪接变体编码的DSG4多肽的细胞外结构域的肿瘤相关抗原的表达 其特征在于缺乏在DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。

    USE OF RNA FOR REPROGRAMMING SOMATIC CELLS
    7.
    发明申请
    USE OF RNA FOR REPROGRAMMING SOMATIC CELLS 审中-公开
    使用RNA进行复制SOMATIC CELLS

    公开(公告)号：US20160122721A1

    公开(公告)日：2016-05-05

    申请号：US14933840

    申请日：2015-11-05

    Applicant: BioNTech AG ,  Johannes Gutenberg Universitat Mainz

    Inventor： Ugur SAHIN ,  Marco POLEGANOV ,  Tim BEISSERT

    IPC: C12N5/074

    CPC classification number: C12N5/0696 ,  C12N2510/00

    Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.

    Abstract translation: 本发明提供了将体细胞分离成干细胞而不产生胚胎或胎儿的方法。 更具体地，本发明提供了通过引入导致体细胞去分化为体细胞并培养体细胞的RNA编码因子来实现体细胞向具有干细胞特征，特别是多能性的细胞去分化的方法 允许细胞去分化。

    IDENTIFICATION OF TUMOR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPY
    8.
    发明申请
    IDENTIFICATION OF TUMOR-ASSOCIATED CELL SURFACE ANTIGENS FOR DIAGNOSIS AND THERAPY 有权
    用于诊断和治疗的肿瘤相关细胞表面抗原的鉴定

    公开(公告)号：US20150376718A1

    公开(公告)日：2015-12-31

    申请号：US14830506

    申请日：2015-08-19

    Applicant: BioNTech AG

    Inventor： Özlem TÜRECI ,  Ugur SAHIN ,  Gerd HELFTENBEIN ,  Volker SCHLÜTER

    IPC: C12Q1/68

    CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/56

    Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

    Abstract translation: 本发明提供具有肿瘤抑制活性的药剂，并且其对表达或异常表达肿瘤相关抗原的细胞是选择性的。 所述肿瘤相关抗原具有选自以下的核苷酸序列：（a）选自本文所述的特定序列的核苷酸序列或其6-50个连续核苷酸残基部分; （b）在严格条件下与具有（a）的核苷酸序列的核酸杂交的核酸的核苷酸序列; （c）相对于（a）或（b）的核苷酸序列退化的核苷酸序列; 和（d）与（a），（b）或（c）的核苷酸序列互补的核苷酸序列。 还提供了包含这些试剂的药物组合物和试剂盒，以及治疗，诊断或监测以肿瘤相关抗原的表达或异常表达为特征的疾病的方法。

Patent Agency Ranking